ReviewInternational journal of clinical and experimental pathology2025
Evaluation of the efficacy and safety of durvalumab combined with chemotherapy, radiotherapy, or other agents in advanced non-small cell lung cancer: a meta-analysis.
Review in International journal of clinical and experimental pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A systematic review and meta-analysis on survival, pathological response, and safety of durvalumab in early-stage non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDurvalumab may improve survival in patients with advanced non-small cell lung cancer (NSCLC) when given as maintenance therapy; nevertheless, further research is required. Durvalumab and other drugs have enhanced survival rates in advanced NSCLC. The optimal therapy combination is uncertain. This trial will evaluate the effectiveness and tolerability of Durvalumab-based combination therapy for advanced NSCLC.
methodsWe searched PubMed, Embase, the Cochrane Library, and Web of Science for relevant papers, obtaining information on overall response rate (ORR), median progression-free survival (mPFS), median overall survival (mOS), and adverse events (AEs).
results13 studies were included that involved a total of 2,277 participants. The ORR of Durvalumab combination therapy in NSCLC was 41.6%, rising to 47.1% within the radiation or chemotherapy cohort. The mPFS was 5.1 months, while the mOS was 13.5 months. The 1-year progression-free survival (PFS) rate was 49.0%, while the 2-year overall survival (OS) rate was 42.9%. In the radiation and chemotherapy subgroups, these rates rose to 53.4% and 61.1%, respectively. The prevalent adverse responses were anemia (31.3%), nausea (18.9%), and fatigue (18.6%).
conclusionsOur meta-analysis demonstrated that Durvalumab combination treatment is both effective and safe for advanced NSCLC, particularly in patients undergoing combined chemoradiotherapy. These results encourage more Phase III studies. The review agreement is recorded on PROSPERO (CRD42024622471) and is on the NIHR HTA program website.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.